Beyond Azacitidine: Investigating new therapeutic targets for the treatment of Myelodysplastic Syndrome [ 2019 - ]

Research Grant

Brief description The drug Azacitidine (AZA) is the best available treatment for patients with the blood cancer Myelodysplastic Syndrome (MDS). However, more than half of the treated patients will never respond to treatment. Furthermore, a significant fraction of the patients will eventually relapse, highlighting a need to develop more effective and durable therapies. Here, we will investigate molecular mechanisms within MDS cells affected by AZA, as a means to develop new treatment options for MDS.

Funding Amount $588,874.00

Funding Scheme Project Grants

Notes New Investigator Grant